Abstract：
Endometriosis is a prevalent condition in women that causes pelvic pain and fertility issues due to the growth of endometrial tissue outside the uterus during menstrual cycles. Steroid hormones play a crucial role in the development and growth of endometriosis lesions; therefore, researchers have investigated several effective drugs that target hormones for treating this disease. One such drug is bazedoxifene, but despite several animal studies, there has yet to be a comprehensive evaluation of their combined results. A systematic search was conducted across several databases (Embase, PubMed, Scopus, and Web of Sciences) to identify studies investigating the effectiveness of bazedoxifene in animal models of endometriosis. Meta-analysis was performed using the size of endometriosis implants before and after drug administration in the case and control groups, along with the p-value of the associations. Begg\'s and Egger\'s tests were used to assess publication bias. This study included four eligible studies consisting of 45 endometrial animal models and 35 control subjects. The meta-analysis showed that bazedoxifene significantly reduced the size of endometriosis implants in animal models compared with the control group (odds ratio: 0.122, 95% confidence interval: 0.050-0.298, p<0.001). Detailed investigation determined that there was no significant heterogeneity between the studies (I2=38.81, and p-value of the Q test=0.179). However, according to Egger\'s test, the study showed publication bias (p=0.035). This study found that bazedoxifene is a promising treatment option for endometriosis in animal models. However, more research on animals and humans is required to confirm these results.
摘要：
子宫内膜异位症是女性的一种常见病，由于月经周期中子宫内膜组织在子宫外的生长而导致盆腔疼痛和生育问题。类固醇激素在子宫内膜异位症病变的发育和生长中起着至关重要的作用；因此，研究人员已经研究了几种有效的针对激素的药物来治疗这种疾病。一种这样的药物是巴泽多昔芬，但是尽管有几项动物研究，尚未对其合并结果进行全面评估。在几个数据库(Embase，PubMed,Scopus,和WebofSciences）以确定研究巴多昔芬在子宫内膜异位症动物模型中的有效性的研究。采用病例组和对照组给药前后子宫内膜异位症植入物大小进行Meta分析,以及关联的p值。Begg和Egger的测试用于评估发表偏倚。这项研究包括四个合格的研究，包括45个子宫内膜动物模型和35个对照受试者。荟萃分析显示，与对照组相比，bazedoxifene在动物模型中显着减小了子宫内膜异位症植入物的大小（比值比：0.122，95％置信区间：0.050-0.298，p<0.001）。详细调查确定研究之间没有明显的异质性（I2=38.81，Q检验的p值=0.179）。然而,根据Egger的测试,研究显示发表偏倚(p=0.035).这项研究发现，巴泽多昔芬是动物模型中子宫内膜异位症的有希望的治疗选择。然而,需要对动物和人类进行更多的研究来证实这些结果。
